Analysis of stool samples is a frequent task in clinical diagnostics. Heike Calado Duarte and Carlo Farah from our R&D team talk to us about the challenges involved and what you should pay [...]
During the COVID-19 pandemic, there were significantly fewer infections with diarrhea-causing pathogens such as norovirus. However, with the relaxation of countermeasures against COVID-19, the number [...]
Respiratory diseases often show similar symptoms, but are triggered by a variety of pathogens, such as viruses, bacteria and fungi. Rapid, comprehensive and reliable diagnostics as a basis for [...]
All RIDA®GENE SARS CoV-2 tests detect the new variant Omicron (B1.1.529) with the usual sensitivity and reliability
The Omicron variant does not show any mutations in the areas detected by our assays and is therefore positively detected by RIDA®GENE SARS-CoV-2 (Art. No. PG6815/ PG6820) and RIDA®GENE Flu & [...]
In the hospital, there is a dangerous visitor: What are the most recent research on Clostridium difficile?
The bacteria Clostridium difficile colonizes every human intestine, although it may be harmful for those with compromised immune systems. It is becoming increasingly prevalent in hospitals. What is [...]
Studies have shown that some patients do not respond or respond inadequately to therapies for chronic intestinal diseases like for example Inflammatory Bowel Disease. The biologic drug ustekinumab, [...]
Therapeutic drug monitoring (TDM) for the biological Vedolizumab has not been in focus to date. Vedolizumab is a meant or the treatment for inflammatory bowel disease. On Wednesday, September 29, our [...]
We complement our control reagent portfolio with new controls including SARS-CoV2 positive and negative controls, as well as all-encompassing validation and verification kits for respiratory and [...]
The COVID-19 infection figures continue to rise and with them the fear: How long can regular school operations be maintained? Experts warn of renewed school closings and recommend specific measures.
Helicobacter pylori can cause serious diseases. The symptoms of a Helicobacter infection vary widely in their form and expression. Detection is therefore critical for diagnosis and treatment. [...]
In February 2020, R-Biopharm was one of the first diagnostics companies worldwide to launch a test kit for the novel coronavirus SARS-CoV-2. Now, the test has received the CE label and is thus [...]
Mississauga, Canada and Darmstadt, Germany, 15th May 2020 – R-Biopharm AG and Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator, announces the appointment of R-Biopharm AG [...]
Infection with the stomach bacteria Helicobacter pylori is the most common cause of stomach inflammation (gastritis). Yet, these widespread bacteria can also cause many other diseases—possibly even [...]
Real-time PCR tests offer many advantages and have become an important part of clinical diagnostics. Yet the efficiency of the tests depends also on the software. With the new, automated evaluation [...]
Highly effective and well tolerated: the anti-inflammatory medication golimumab, known under the trade name Simponi®, is a valuable treatment option for patients with rheumatic diseases as well as [...]
The intestinal bacterium Clostridium difficile is one of the most common causes of nosocomial infections. Patients whose intestinal flora is disrupted due to the use of antibiotics are particularly [...]
As temperatures grow colder, the risk of catching the flu virus and spreading the infection among the population rises as well. But what makes the influenza virus so dangerous? For Virus Appreciation [...]
Sexually transmitted infections/diseases (STIs or STDs) like syphilis, gonorrhea, and chlamydia are on the rise worldwide. But still hardly anyone talks about it.
aprimeo diagnostics GmbH & Co. KG, a R-Biopharm AG company, starts distribution of the new innovative molecular diagnostics platform Vivalytic from Bosch
More than five million people worldwide suffer from chronic inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis. World IBD Day on May 19 brings awareness to this [...]
Adalimumab (ADM) revolutionized the treatment of patients with inflammatory bowel diseases. Despite its therapeutic success, up to 40 % of patients do not respond to adalimumab induction treatment [...]
As allergies become more widespread, their diagnosis takes on an important role. For this purpose, laboratory tests that detect allergen-specific antibodies in the blood are indispensable tools. [...]
Patients with Crohn’s disease, ulcerative colitis or other inflammatory diseases are often treated with adalimumab. However, long-term therapy success is not always achieved. As a recent study [...]
RIDA®QUICK ADM Monitoring is a rapid test for adalimumab drug concentration monitoring which supports timely dose adjustments in clinical practice. A poster about the validation of the test was [...]
Clostridium difficile is one of the most frequent pathogens in nosocomial infections – but in spite of this many people have never heard of it. Since November is officially “Clostridium [...]
An estimated 540 million people worldwide suffer from lower back pain. When the pain becomes chronic, a rheumatic illness such as Bechterew’s disease may be the cause.
The year’s wet and cold season begins in October along with the annual flu season. After an extraordinarily severe flu wave in 2017/18, experts are warning that the flu should not be underestimated.
Through early detection, almost all colorectal cancers can be cured or even prevented. The exam is effective and simple – and it is not performed often enough. The new invitation process is [...]
Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, and rheumatism respond well to treatment with the TNF-α blockers infliximab and adalimumab. Monitoring the concentration [...]
More than half of the world’s population suffers from an inflammation of the gastric mucosa called gastritis. These patients are at risk of developing a gastric ulcer, a duodenal ulcer or even [...]
The guideline of the Joint National Committee (G-BA) requires laboratories to switch to a new test procedure for early detection of colon cancer. We have summarized what you need to consider in [...]
Now that summer is here, people are spending more and more time outside. Warm temperatures certainly make activities like swimming, hiking, jogging and picnicking more attractive. But forests and [...]
R-Biopharm enters into collaboration with Statens Serum Institute in the field of tuberculosis diagnostics
Darmstadt, Germany, June 27, 2018 – R-Biopharm Group announced today a collaborative agreement with Statens Serum Institute (SSI, Denmark), focusing on discovery and development of novel diagnostic [...]
The new generation of the RIDA®GENE multiplex real-time PCR kits offers a number of improvements—and makes molecular laboratory diagnostics even more efficient and flexible.
The lab — a place for science and research where experiments and tests are on the daily agenda. Yet the world of the laboratory is changing. Digitalization and automation mark a new era. For World [...]
R-Biopharm and ELITechGroup announced a worldwide agreement to expand their real-time PCR assay portfolio
Darmstadt, Germany and Puteaux, France, April 19, 2018 – R-Biopharm, a globally active life science company, and ELITechGroup, a leading company in sample-to-result molecular diagnostics, announced [...]
Sexually transmitted infections/diseases (STIs or STDs) like syphilis, gonorrhea, and chlamydia are on the rise worldwide. But hardly anyone talks about it. To mark STD Awareness Month, we explain [...]
In Germany, more than 60,000 people contract colon cancer every year; over 25,000 die of the disease. Early detection could have prevented many such cases – yet in spite of that, only one in every [...]
R-Biopharm AG & Bosch Healthcare Solutions partner to develop molecular diagnostics for automated all-in-one platform
R-Biopharm AG today announced that it has entered into a collaboration with Bosch Healthcare Solutions. Under the agreement, R‑Biopharm AG develops, manufactures and commercializes molecular [...]
As temperatures grow colder, the risk of catching the flu virus rises as well. This year, Australia is experiencing the worst flu epidemic in 15 years. Are Europe and North America also facing the [...]
Microspot arrays facilitate efficient and high-quality multiplex diagnostics for any sample throughput. They are also convenient, flexible, and automatable. This innovative technology is available [...]
Zoonoses are infectious diseases which can be transmitted from animals to humans. More than 200 of these diseases are known. On World Zoonoses Day on July 6 we are presenting the most common [...]
Can you tolerate these foods? More and more people can’t due to food allergies. On the occasion of Food Allergy Day, we reported last week on type I allergies. Today, we will devote our [...]
Not all allergies are alike. At the food allergy awareness day on June 21st, we will be dealing with food allergies in children and will show what is actually important for a diagnosis.
The drug adalimumab is used very successfully in the treatment of various inflammatory diseases. Yet in some patients, the efficacy of this drug decreases over time. We explain why this is so and how [...]
May is completely characterized by intestinal health: first Digestive Disease Week, now World IBD Day. The aim of the IBD action day is to raise awareness about inflammatory bowel diseases (IBDs). [...]
Therapeutic drug monitoring (TDM) is used to measure the concentration of an active ingredient in the patient’s blood. Using this information, physicians can adjust the dose individually to the [...]
Tick season has started and the risk of dangerous infections with TBE/FSME is increasing. In the event of a suspected infection and to clarify immunization, antibody detection is the method of choice.
As every year, March is officially “Colon Cancer Awareness Month”. A great opportunity to highlight the importance of screening. Nowadays, modern tests have made the early detection of colon [...]
So-called TNFα blockers are commonly used in the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. Therapeutic drug monitoring improves the effect of the [...]
RIDA®GENE Helicobacter pylori is a sensitive and specific real-time PCR assay. It simultaneously detects and differentiates Helicobacter pylori and its resistance to clarithromycin in human tissue [...]
R-Biopharm starts RIDA qLine® Allergy External Quality Assessment. This new tool will help to ensure the quality of the testing procedures in laboratories using RIDA qLine® Allergy and the [...]
The RIDA®GENE real-time PCR assays (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) successfully detected the suggested vaccination strains for influenca of the 2015/2016 season.
Chronic inflammatory bowel disease (IBD) is characterized by recurring and often ongoing flares. The most common forms of IBD are Crohns disease and Ulcerative colitis.
It is often difficult to differentiate patients with inflammatory bowel disease (IBD) those who suffer from irritable bowel syndrome due to similar symptoms of patients. Both groups show similar [...]
According to the Robert Koch Institute (RKI) every year 63.000 people in Germany fall ill with colon cancer. Approximately 25,000 people die annually from the consequences of this disease. Colon [...]
TNFalpha blocker are biologic agents, which are used for the treatment of inflammatory diseases such as Ulcerative Colitis, Crohns disease and Rheumatoid Arthritis. Infliximab as well as Adalimumab [...]
Molander et al. investigated if concentrations of fecal calprotectin can be used for predicting relaps after stopping TNFα blocking therapy in patients with Ulcerative Colitis and Morbus Crohn.
Study about first randomized, controlled testing shows that clinical treatment decisions based on therapeutic drug monitoring (TDM) is superior to dose-intensification strategy.
The RIDA®GENE real-time PCR assays for the detection of Influenza (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) detect the currently circulating drift variant of influenza A (H3N2).
Ann Gils and her colleagues from KU Leuven evaluated if the biosimilars were equally well quantified as the original infliximab (IFX) drug in their clinically validated infliximab assay.
Community-acquired pneumonia (CAP) is the most common fatal infectious disease in western countries. Bacteria are the most common pathogens causing CAP, where one differentiates between typical and [...]
Sustainable excellence in longterm and profitable growth awarded After awards in 2010 and 2013, R-Biopharm AG has won the Deloitte Sustained Excellence Award for the third time in a row this [...]
About 50 % of Type-1-Diabetics, 33 % Type-2-Diabetics and 75 – 80 % Mucoviscidosis patients develop exocrine pancreatic insufficiency in the course of their illness (Hardt PD, Pancreatology, [...]
R-Biopharm AG has faced the challenge to develop a sophisticated allergy in vitro test system that combines both a quantitative determination and a very economic and easy handling.
New line blot immunoassays – reliable differentiation between human IgG and IgA antibodies against Helicobacter pylori type I and II strains
R-Biopharm (Darmstadt) has brought to the market the fastest assay currently available for the specific detection of enterohemorrhagic Escherichia coli (EHEC). With the new RIDA®GENE EHEC/EPEC rapid [...]
The Danish company REFLAB became a member of the R-Biopharm group on January 1, 2010. As a supplier of test kits for the detection of autoreactive urticaria and histamine release tests for the [...]